info@ceoworld.biz
Wednesday, November 6, 2024
CEOWORLD magazine - Archive in Frank Watanabe

Frank Watanabe

Frank Watanabe

Frank Watanabe has been the president of Arcutis Biotherapeutics since 2016, and chief executive officer since 2017. Prior to joining Arcutis, he was co-founder and chief operating officer of Kanan Therapeutics, a cardiovascular drug development company, and before that, was vice president of strategy and corporate development at Kythera Biopharmaceuticals.

Mr Watanabe was an executive at Amgen, Inc. from 2005 to 2013, where he was involved in the development of Repatha® for hyperlipidemia and Aimovig® for migraine, and worked on the US marketing of Enbrel® in both dermatology and rheumatology. Previously, he was an executive with Eli Lilly and Company, and an official in the US government. He was also a commissioned officer in the US Navy Reserves for 25 years. He formerly served on the board of Amunix Pharmaceuticals. Mr Watanabe earned his MA in national security studies, and his BA in international relations, both at Georgetown University.

Frank Watanabe is an opinion columnist for the CEOWORLD magazine. Connect with him through LinkedIn.
Frank Watanabe
CEO Insider

Is It Time to Rethink Paid Time Off?

CEO InsiderFrank Watanabe
Many aspects of the workplace have evolved in the past century, with some accelerating in the past few years, catalyzed by the massive workplace disruptions wrought by the COVID pandemic.  One facet that has proven surprisingly resistant to change, however, is companies’ approach to paid time off (PTO). At last,...